Predictors of Blood Pressure Response to the Angiotensin Receptor Blocker Candesartan in Essential Hypertension
Open Access
- 1 January 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 21 (1), 61-66
- https://doi.org/10.1038/ajh.2007.24
Abstract
Response to antihypertensive drugs varies widely among individuals. We studied characteristics that might be predictive of blood pressure (BP) response in 203 African-American and 236 non-Hispanic white subjects with essential hypertension treated with candesartan, 32 mg/day for 6 weeks, after a drug-free washout period of at least 4 weeks (baseline). Measurements at enrollment, baseline, and at the end of the treatment were incorporated into linear regression models to quantify their additive contributions to predicting response. Enrollment measurements predictive of a greater response were non-Hispanic white ethnicity, female gender, the interaction between ethnicity and gender, and lower body weight. Of baseline measurements, higher BP and higher plasma renin activity (PRA) made additional contributions to predicting a greater response. Of the measurements made at the end of the study, only a larger increase in PRA from baseline contributed to predicting a greater response. The combined effects of all the identified predictors accounted for 39 and 33% of the interindividual variation in systolic and diastolic BP responses, respectively (P < 0.001 for both). These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB).Keywords
This publication has 25 references indexed in Scilit:
- Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialHypertension, 2006
- Overlap Between Whites and Blacks in Response to Antihypertensive DrugsHypertension, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Evidence From New Hypertension TrialsHypertension, 2004
- Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000JAMA, 2003
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Genetics of blood pressure, hypertensive complications, and antihypertensive drug responsesPharmacogenomics, 2003
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJAMA, 2002
- Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertensionKidney International, 2002
- Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with PlaceboNew England Journal of Medicine, 1993
- Searching out low renin patients: Limitations of some commonly used methodsAmerican Journal Of Medicine, 1973